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Glutamate transporter solute carrier family 1, member 2 (GLT1/EAAT2), a major
modulator of glutamate homeostasis in astrocytes, is assessed in post-mortem human
brain samples of frontal cortex area 8 in advanced stages of Alzheimer disease (AD) and
terminal stages of dementia with Lewy bodies (DLB) in order to gain understanding of
astrogliopathy in diseases manifested by dementia. Glial fibrillary acidic protein (GFAP)
mRNA expression is significantly increased in AD but not in DLB, whereas GLT1,
vesicular glutamate transporter 1 (vGLUT1) and aldehyde dehydrogenase 1 family
member 1 (ALDH1L1) are not modified in AD and DLB when compared with controls.
GLT1 protein levels are not altered in AD and DLB but GFAP and ALDH1L1 are
significantly increased in AD, and GFAP in DLB. As a result, a non-significant decrease
in the ratio between GLT1 and GFAP, and between GLT1 and ALDH1L1, is found
in both AD and DLB. Double-labeling immunofluorescence and confocal microscopy
revealed no visible reduction of GLT1 immunoreactivity in relation to β-amyloid plaques
in AD. These data suggest a subtle imbalance between GLT1, and GFAP and
ALDH1L1 expression, with limited consequences in glutamate transport.
Keywords: Alzheimer disease, dementia with Lewy bodies, glutamate transporter 1, EAAT2, vGLUT1, glial fibrillary
acidic protein, ALDH1L1
INTRODUCTION
Alzheimer disease (AD), the main cause of dementia in old age, is characterized by β-amyloid
deposition forming plaques and amyloid angiopathy, and hyperphosylated tau in neurons with
neurofibrillary tangles (NFTs) and pre-tangles, dystrophic neurites of senile plaques, and neuropil
threads (Duyckaerts and Dickson, 2011; Ferrer, 2012; Braak and Del Tredici, 2015). NFTs increase
in number and distribution from stages I-II to stages V-VI with generalized involvement of
the neocortex (Braak and Braak, 1991). Amyloid plaque burden also increases with disease
progression from stages A (low density of plaques in the isocortex), B (medium density of plaques
in the associative isocortex) and C (high density of plaques in motor and sensory isocortex)
although there are important individual variations not related to NFTs (Braak and Braak, 1999).
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β-amyloid deposition has been categorized into phase 1 involving
the neocortex, phase 2 with additional involvement of the
allocortex, phase 3 involving the diencephalic nuclei, striatum,
and cholinergic nuclei of the basal forebrain, phase 4 involving
several nuclei of the brain stem, and phase 5 with cerebellar
involvement (Thal et al., 2002).
Dementia with Lewy bodies (DLB), the second most common
neurodegenerative dementia in the elderly, is pathologically
characterized by Lewy bodies and Lewy neurites, composed
of abnormal α-synuclein in the brainstem, limbic system and
cortical areas (McKeith et al., 2004; Fujishiro et al., 2008; Ince,
2011).
Glutamate transporter solute carrier family 1, member 2
(GLT1/EAAT2) expressed in astrocytes regulates glutamate
levels at the synapse and plays a cardinal role in preventing
excitotoxic neuronal damage in certain neurodegenerative
diseases (Nedergaard et al., 2002; Maragakis and Rothstein,
2006). Expression levels of GLT1 and glutamate homeostasis in
prefrontal cortex in AD are controversial as they are reported
to be decreased in some studies (Masliah et al., 1996) and
preserved in others (Kulijewicz-Nawrot et al., 2013). An inverse
relation between increased Glial fibrillary acidic protein (GFAP)
and reduced GLT1 is described in AD with disease progression
as defined by Braak stage of NFT pathology (Simpson et al.,
2010, 2011). Indirect data point also to functional alterations of
glutamate transporters in AD as a result of oxidative damage
(Lauderback et al., 2001), altered solubility (Woltjer et al., 2010),
and splice variants (Scott et al., 2011). Altered mRNA and/or
protein expression of glutamate transporters have been reported
in transgenic models of AD (Masliah et al., 2000; Cassano
et al., 2012). Astrocytes in transgenic mice expressing mutant
A53T α-synuclein have reduced expression of GLT1 (Gu et al.,
2010) but there is no information, as far as we know, regarding
GLT1 expression in DLB.
The present study analyses GLT1 mRNA and protein
expression in frontal cortex in AD and DLB in a series of post-
mortem human brains in order to learn about the possible
implication of this astrocytic glutamate transporter in the
pathogenesis of these diseases.
MATERIALS AND METHODS
Human Cases
Brain tissue was obtained from the Institute of Neuropathology
HUB-ICO-IDIBELL Biobank and the Hospital Clinic-IDIBAPS
Biobank following the guidelines of Spanish legislation on this
matter (Real Decreto de Biobancos 1716/2011) and approval
of the local ethics committees. Processing of brain tissue has
been detailed elsewhere (Ferrer, 2014). One hemisphere was
immediately cut in coronal sections, 1 cm thick, and selected
areas of the encephalon were rapidly dissected, frozen on metal
plates over dry ice, placed in individual air-tight plastic bags,
and stored at −80◦C until use for biochemical studies. The
other hemisphere was fixed by immersion in 4% buffered
formalin for 3 weeks for neuropathological studies as detailed
elsewhere (Ferrer, 2014). Neuropathological diagnosis of AD was
categorized following Braak stages of NFT pathology adapted
to paraffin sections (Braak and Braak, 1991; Braak et al.,
2006) and Thal phases of β-amyloid plaques (Thal et al.,
2002). DLB was diagnosed following accepted neuropathological
criteria (Braak et al., 2003; McKeith et al., 2004; Alafuzoff
et al., 2009). Middle-aged control cases (MA) had not suffered
from neurological or psychiatric diseases, infections of the
nervous system, brain neoplasms, systemic and central immune
diseases, or metabolic diseases (including metabolic syndrome),
and did not have abnormalities in the neuropathological
examination excepting stages I–II of NFT pathology and phases
1–2 of β-amyloid plaques. Cases with associated pathologies
such as vascular diseases (excepting mild atherosclerosis and
arteriolosclerosis), TDP-43 proteinopathy, metabolic syndrome
and hypoxia were excluded from the present study.
MA cases were 22 men and 17 women (n = 39, mean age
61.8 ± 14.0 years). AD cases, categorized as stages V–VI of
NFT and phases 3–4 of β-amyloid, were 9 men and 11 women
(n = 20, mean age 80.5 ± 6.9 years). DLB, categorized as stages
5–6 of Parkinson’s disease-related pathology, Thal phase 3–4,
and NFT stages III–IV, were 8 men and 1 woman (n = 9, mean
age 76.4 ± 5.7). The post-mortem delay was between 3 h and 9 h
35 min in MA, 2 h 30 min and 17 h 30 min in AD, and 5 h and
9 h in DLB cases.
RNA Purification
Purification of RNA from right frontal cortex area 8 of
human frozen brain was carried out using RNeasy Lipid
Tissue Mini Kit (Qiagen, Hilden, Germany) following the
protocol provided by the manufacturer combined with DNase
digestion to avoid extraction and later amplification of genomic
DNA. The concentration of each sample was obtained from
A260 measurements with a NanoDrop 2000 spectrophotometer
(Thermo Scientific, Waltham, MA, USA). RNA integrity was
tested using the Agilent 2100 BioAnalyzer (Agilent, Santa Clara,
CA, USA). Values of RNA integrity number (RIN) were between
6.4 and 8.4 in MA, between 6.4 and 9.1 in AD, and between
5.2 and 7 in DLB. Bivariate analyses were carried out to
detect association of our variables with potential confounding
factors (age, post-mortem delay and RIN) using Spearman or
Pearson correlations for quantitative variables (data not shown).
Statistical analysis was performed with GraphPad Prism version
5.01. post-mortem delay had no effect on RIN values in MA, AD
and DLB cases.
Retrotranscription Reaction
Retrotranscription reaction of RNA samples was carried out
with the High-Capacity cDNA Archive kit (Applied Biosystems,
Foster City, CA, USA) following the guidelines provided by the
supplier, and using Gene Ampr 9700 PCR System thermocycler
(Applied Biosystems). A parallel reaction for one RNA sample
was processed in the absence of reverse transcriptase to rule out
DNA contamination.
Real Time PCR
Real Time quantitative PCR (RT-qPCR) assays were conducted
in duplicate on 1000 ng of cDNA samples obtained from
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the retro-transcription reaction, diluted 1:20 in 384-well
optical plates (Kisker Biotech, Steinfurt, Germany) utilizing
the ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems). Parallel amplification reactions were carried out
using 20× TaqMan Gene Expression Assays and 2× TaqMan
Universal PCR Master Mix (Applied Biosystems). Parallel assays
for each sample were carried out using β-glucuronidase (GUS-B),
X-prolyl aminopeptidase (aminopeptidase P) 1 (XPNPEP1) and
alanyl-transfer RNA synthase (AARS) probes for normalization.
The selection of these housekeeping genes was based on
previous data showing low vulnerability in the brain of several
human neurodegenerative diseases (Barrachina et al., 2006;
Durrenberger et al., 2012). The reactions were performed
using the following parameters: 50◦C for 2 min, 95◦C for
10 min, 40 cycles at 95◦C for 15 s and 60◦C for 1 min.
TaqMan PCR data were captured using the Sequence Detection
Software (SDS version 2.2, Applied Biosystems). Subsequently,
threshold cycle (CT) data for each sample were analyzed with
the double-delta CT (∆∆CT) method. First, delta CT (∆CT)
values were calculated as the normalized CT values for each
target gene in relation to the mean values of GUS-β, XPNPEP1
and AARS. Second, ∆∆CT values were obtained with the
∆CT of each sample minus the mean ∆CT of the population
of control samples (calibrator samples). The fold-change was
determined using the equation 2−∆∆CT. Genes analyzed with
the corresponding abbreviations and TaqMan probes used
in the study are shown in Table 1. Pearson’s correlation
coefficient was used to assess a possible linear association
between two continuous quantitative variables. To determine the
relationship between gene expression and RIN values according
to pathologic variables, we used the analysis of covariance. No
significant correlations were found testing gender with diagnosis,
post-mortem delay and RIN values. Taking into account that
each group of pathological cases (AD and DLB) were processed
in parallel with its respective group of controls, but not both
pathologies in the same RT-qPCR plate, statistical t-test was
chosen to compare sample groups instead of One-way ANOVA.
Thus, statistical t-test was performed to analyze each pathological
group with its respective control. Significant p-value: ∗∗p < 0.01.
Gel Electrophoresis and Western Blotting
From Total Homogenate
Tissue was processed as reported elsewhere (Garcia-Esparcia
et al., 2015). A total of 0.1 g of frozen tissue from frontal
cortex area 8 of all MA, AD and DLB cases was lysed with
a glass homogenizer in Mila lysis buffer (0.5 M Tris at pH
7.4 containing 0.5 methylenediaminetetraacetic acid at pH 8.0,
5M NaCl, 0.5% Na deoxycholic acid, 0.5% Non-idet P-40,
1 mM phenylmethylsulfonyl fluoride, bi-distilled water, and
protease and phosphatase inhibitor cocktails (Roche Molecular
Systems, Pleasanton, CA, USA)), and then centrifuged for
15 min at 13,000 rpm at 4◦C (Ultracentrifuge Beckman with
70Ti rotor, CA, USA). Protein concentration was measured
with SmartspectTM plus spectrophotometer (Bio-Rad, CA, USA)
using the Bradford method (Merck, Darmstadt, Germany).
Samples containing 15 µg of protein and the standard
Precision Plus ProteinTM Dual Color (Bio-Rad) were loaded
onto 10% acrylamide gels. Proteins were separated with
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and electrophoretically transferred to nitrocellulose
membranes using the Trans-BlotTurbo transfer system (Bio-
Rad) at 200 mA/membrane for 60 min. Non-specific bindings
were blocked by incubation with 5% milk in Tris-buffered saline
(TBS) containing 0.1% Tween for 1 h at room temperature. After
washing, the membranes were incubated at 4◦C overnight with
appropriate primary antibodies. Anti-GLT1 (Ab1783, Merck
Millipore, Darmstadt, Germany) and anti-ALDH1L1 (ab56777,
Abcam, Cambridge, UK) were used at a dilution of 1:500 in
TBS containing 3% albumin and 0.1% Tween; both antibodies
were detected after 1 h incubation with the appropriate
HRP-conjugated secondary antibody (1:2000, Dako, Glostrup,
Denmark), and the immune complexes were revealed with a
chemiluminescence reagent (ECL, Amersham, GE Healthcare,
Buckinghamshire, UK). Membranes were washed and incubated
for 1 h with anti-β-actin antibody (1:30,000, A5316; Sigma-
Aldrich, St. Louis, MO, USA), and blotted to control protein
loading. After the immune complexes were revealed, membranes
were stripped and blocked again by incubation with 5% milk in
TBS containing 0.1% Tween for 1 h at room temperature. Once
membranes were washed, they were incubated at 4◦C overnight
with rabbit anti-human GFAP (1:30,000, Z0334, Dako, Glostrup,
Denmark) and detected after 1 h of incubation with anti-rabbit
HRP-conjugated secondary antibody (1:2000, Dako, Glostrup,
Denmark), and the immune complexes were revealed with
ECL chemiluminescence reagent. Quantification of western blot
optical densities (O.D.) was performed using ImageJ software
(Bethesda, MD, USA), and analyzed with GraphPad Prism
version 5.01 software (La Jolla, CA, USA) and Statgraphics
TABLE 1 | Taqman probes used in the present study including housekeeping genes (GUS-B, XPNPEP1 and AARS), glutamate transporter 1 (GLT1), vesicular glutamate
transporter 1 (vGLUT1), aldehyde dehydrogenase 1 family member 1 (ALDH1L1) and glial fibrillary acidic protein (GFAP).
Gene Full name Reference
Housekeeping genes
GUS-B β-glucuronidase Hs00939627_m1
XPNPEP1 X-prolylaminopeptidase (aminopeptidase P) 1 Hs00958026_m1
AARS Alanyl-tRNA synthetase Hs00609836_m1
Genes analyzed
GLT1 Glutamate transporter 1 Hs01102423_m1
vGLUT1 Vesicular glutamate transporter 1 Hs00220404_m1
ALDH1L1 Aldehyde dehydrogenase 1 family member 1 Hs01003842_m1
GFAP Glial fibrillary acidic protein Hs00909233_m1
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FIGURE 1 | mRNA expression of GLT1, vGLUT1, Glial fibrillary acidic protein (GFAP) and ALDH1L1 in frontal cortex area 8 in Alzheimer disease (AD) and dementia
with Lewy bodies (DLB). Mean expression of housekeeping genes GUS-B, XPNPEP1 and AARS was used to normalize samples. Variations are represented as
Fold-change. No significant differences are observed regarding GLT1 (A), vGLUT1 (B), ALDH1L1 (C) expression in AD and DLB compared with middle-aged control
cases (MA). (D) In contrast, significant increase in GFAP mRNA is found in AD but not in DLB. Statistical t-test was performed to compare each group. p values are
depicted in every analysis. Significant p-value stated at ∗∗p < 0.01.
Statistical Analysis and Data Visualization Software version
5.1 (Warrenton, VA, USA). Statistical t-test was performed
to analyze each group with its respective control; significant
p-values were established as: ∗p < 0.05 and ∗∗p < 0.01.
Double-Labeling Immunofluorescence and
Confocal Microscopy
For double-labeling immunofluorescence and confocal
microscopy, de-waxed sections, 4 µm thick, of frontal cortex
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FIGURE 2 | Protein expression levels of GLT1, ALDH1L1 and GFAP in frontal cortex in AD and DLB compared with MA. β-actin is used as control of protein loading
(A). No significant differences in the levels of GLT1 are found in AD and DLB compared with MA. However, significantly increased protein levels of ALDH1L1 are
noted in AD, but not in DLB compared with MA. No significant differences, but just a trend to decrease, are found in the ratio between GLT1 and ALDH1L1 (B).
Significant increase in GFAP levels is found in AD and DLB when compared with MA cases. As a result, the ratio between GLT1 and GFAP is markedly reduced,
although without statistical significance, in AD and DLB (C). Statistical t-test: ∗p < 0.05, ∗∗p < 0.01. Ratios of optical densities between GLT1 and GFAP, and
GLT1 and ALDH1L1 in MA are ascribed as value 1.
Frontiers in Aging Neuroscience | www.frontiersin.org 5 April 2018 | Volume 10 | Article 122
Garcia-Esparcia et al. GLT1 in Neurodegenerative Diseases With Dementia
area 8 were stained with a saturated solution of Sudan black
B (Merck Millipore, Darmstadt, Germany) to block the
autofluorescence of lipofuscin granules present in cell bodies
(15 min), and then rinsed in 70% ethanol and washed in
distilled water. The sections were boiled in citrate buffer
to enhance antigenicity and blocked for 30 min at room
temperature with 10% fetal bovine serum diluted in PBS. The
sections were incubated at 4◦C overnight with combinations of
primary antibodies GLT1 (1:500, Merck Millipore, Darmstadt,
Germany), GFAP (1:400, Dako, Glostrup, Denmark) and
β-amyloid (1:50, Sigma, St. Louis, MO, USA). After washing,
the sections were incubated with Alexa488 or Alexa546
(1:400, Molecular Probes, Waltham, MA, USA) fluorescence
secondary antibodies against the corresponding host species.
Nuclei were stained with DRAQ5TM (1:2000, Biostatus,
Leicestershire, UK). After washing, the sections were mounted
in Immuno-Fluore mounting medium (ICN Biomedicals,
Irvine, CA, USA), sealed, and dried overnight. Sections were
examined with a Leica TCS-SL confocal microscope (Wetzlar,
Germany).
RESULTS
GLT1, vGLUT1, ALDH1L1 and GFAP mRNA
Expression in AD and DLB
No differences in the expression levels of GLT1 were detected in
frontal cortex area 8 in AD and DLB when compared with MA
cases (Figure 1A).
No differences in the expression levels of vGLUT1 were
detected in frontal cortex area 8 in AD and DLB when compared
with MA (Figure 1B).
No differences in the expression of ALDH1L1 were found
in frontal cortex area 8 in AD and DLB compared with MA
(Figure 1C).
Significant differences in GFAP mRNA expression (p < 0.01)
were seen between AD and MA cases. Yet no differences were
observed between DLB and MA (Figure 1D).
GLT1, ALDH1L1 and GFAP Protein Levels
in AD and DLB
Protein levels of GLT1, ALDH1L1 and GFAP were assessed with
gel electrophoresis and western blotting using β-actin as control
of protein loading (Figure 2A).
GLT1 protein levels showed a tendency to decrease in
AD and DLB without statistical significance. In contrast,
ALDH1L1 protein levels were significantly increased in AD
(p < 0.05) but not in DLB. As a result, the ratio between
GLT1 and ALDH1L1 showed a trend to decrease without
statistical significance in AD and DLB (Figure 2B).
GFAP protein levels were significantly increased in AD and
DLB (p < 0.05 and p < 0.01, respectively). The ratio between
optical densities of GLT1 and GFAP in MA cases was considered
as ratio 1. The ratio between optical densities of GLT1 and
GFAP showed a non-significant decrease in AD and DLB when
compared with MA (Figure 2C).
FIGURE 3 | Double-labeling immunofluorescence and confocal microscopy of
GLT1 (green), β-amyloid (red; B,C,E,F), and GFAP (red; H,I) in frontal cortex
area 8 in AD. GLT1 immunoreactivity is preserved in the vicinity of β-amyloid
plaques (A–F). Astrocytes surrounding small β-amyloid deposit (asterisk) show
preserved GLT1 immunoreactivity at the cell membrane (G–I). Paraffin
sections, nuclei (blue) are stained with DRAQ5TM; (A–C), bar = 50 µm; (D–F),
bar = 15 µm; (G–I), bar = 20 µm.
Double-Labeling Immunofluorescence and
Confocal Microscopy
Double-labeling immunofluorescence and confocal microscopy
disclosed preservation of GLT1 immunofluorescence
surrounding β-amyloid plaques (Figures 3A–F). At higher
magnification, astrocytes showed GLT1 immunofluorescence at
the cell membrane (Figures 3G–I).
DISCUSSION
Present observations show preserved GLT1 mRNA expression
in cerebral cortex area 8 in AD and when compared with MA
individuals. A tendency of GLT1 protein levels to decrease,
with no statistical significance, is found by western blotting
in AD and DLB. Moreover, GLT1 immunoreactivity localizes
equally in reactive astrocytes in the vicinity of β-amyloid plaques
and in astrocytes with no apparent association with plaques.
This would suggest no modifications of GLT1 expression
in AD. In contrast, significant increase of GFAP mRNA
and protein expression occurs in AD and DLB. Therefore,
GLT1 protein levels do not parallel GFAP protein levels in
frontal cortex in AD and DLB. This observation is in line
with previous reports indicating an inverse relation between
increased GFAP expression and reduced GLT1 expression with
disease progression in AD (Simpson et al., 2010, 2011). This is
further demonstrated by analyzing the ratio between GLT1 and
GFAP protein levels. A decreased ratio, although not significant,
occurs in AD and DLB, thus suggesting an imbalance between
GFAP and GLT1 expression in astrocytes in these diseases.
However, this interpretation must be taken with caution as
not all astrocytes express GFAP and other astrocyte markers
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may not be expressed in GFAP-immunoreactive astrocytes
(Kimmelberg, 2004; Sofroniew and Vinters, 2010; Oberheim
et al., 2012).
ALDH1L1 has been used as a marker of total astrocytes
(Ferrer, 2017). No significant differences in ALDH1L1 mRNA
expression are seen in AD and DLB when compared with MA.
However, significant increase in ALDH1L1 protein levels is
found in AD but not in DLB, thus indicating an increase in
the number of astrocytes in AD when compared with MA. The
ratio between ALDH1L1 and GLT1 is decreased, although not
significantly, in AD and DLB, thus suggesting an imbalance
between the total number of astrocytes and GLT1 protein levels.
These subtle differences do not necessarily indicate primary
alterations in the production of GLT1 in astrocytes, but
rather secondary adaptations to neuronal dysfunction.
GLT1 expression depends on the number of functional synapses
under physiological and pathological conditions (Kugler and
Schleyer, 2004; Genoud et al., 2006; Yang et al., 2009). Since
synaptic connectivity is reduced in frontal cortex in AD and
DLB (Jellinger, 2000; Selkoe, 2002; Hashimoto and Masliah,
2003; Gong and Lippa, 2010; Schulz-Schaeffer, 2010; Ferrer,
2012; de Wilde et al., 2016; Santpere et al., 2017), the possibility
of reduced GLT1 expression secondary to decreased synaptic
activity must not be overlooked in AD and DLB.
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